Basten A, McLeod J G, Pollard J D, Walsh J C, Stewart G J, Garrick R, Frith J A, Van Der Brink C M
Lancet. 1980 Nov 1;2(8201):931-4. doi: 10.1016/s0140-6736(80)92100-5.
A 2-year prospective double-blind trial of the treatment of multiple sclerosis patients with the leucocyte extract, transfer factor (TF), obtained from leucocytes of relatives living with the patient, was conducted. 60 patients with definite MS, of whom 58 completed the trial, were divided into two equal groups, one of which received TF and the other placebo. The groups were evenly balanced with respect to sex ratios, disability, duration of disease, ratio of moderate to severe cases, and HLA phenotype. Neurological, electrophysiological, and immunological assessments were done at the start of the trial and every 6 months thereafter. The results indicated that (1) TF retarded but did not reverse progression of the disease; (2) a significant difference between treatment and placebo groups was not apparent with 18 months after the start of the trial; and (3) treatment was effective only in those patients with mild to moderate disease activity.
对多发性硬化症患者进行了一项为期两年的前瞻性双盲试验，使用从与患者共同生活的亲属白细胞中提取的白细胞提取物——转移因子（TF）进行治疗。60例确诊为多发性硬化症的患者（其中58例完成试验）被平均分为两组，一组接受TF治疗，另一组接受安慰剂治疗。两组在性别比例、残疾程度、病程、中重度病例比例和HLA表型方面均衡一致。在试验开始时及此后每6个月进行神经学、电生理学和免疫学评估。结果表明：（1）TF延缓了疾病进展，但并未使其逆转；（2）试验开始18个月后，治疗组与安慰剂组之间未出现显著差异；（3）治疗仅对疾病活动度为轻度至中度的患者有效。
